ATW SPAC Management’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

ATW SPAC Management’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-311,040	Closed	-$40.4K	–	140
2024 Q4	$40.4K	Hold	311,040	–	–	0.05%	55
2024 Q3	$34K	Hold	311,040	–	–	0.04%	76
2024 Q2	$31.1K	Hold	311,040	–	–	0.04%	84
2024 Q1	$46.6K	Hold	311,040	–	–	0.06%	69
2023 Q4	$46.6K	Hold	311,040	–	–	0.07%	62
2023 Q3	$71.5K	Hold	311,040	–	–	0.1%	59
2023 Q2	$59.5K	Buy	+311,040	New	+$54.2K	0.04%	83

ATW SPAC Management's BLACR Position: Q1 2025 in Review

ATW SPAC Management sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 311,040 shares — an estimated $40.4K sold.

ATW SPAC Management first reported a position in BLACR in Q2 2023 and held it in 7 quarters. The position peaked at $71.5K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

ATW SPAC Management reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
ATW SPAC Management sold 311,040 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $40.4K.
ATW SPAC Management first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q2 2023 and held it in 7 quarters.
ATW SPAC Management's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $71.5K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on ATW SPAC Management's 13F filing for Q1 2025, filed 14 May 2025.